Carisma Therapeutics
CARM
CARM was delisted on the 10th of October, 2025.
45 hedge funds and large institutions have $32.3M invested in Carisma Therapeutics in 2020 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 17 increasing their positions, 8 reducing their positions, and 3 closing their positions.
1,082% more call options, than puts
Call options by funds: $650K | Put options by funds: $55K
167% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 3
139% more capital invested
Capital invested by funds: $13.5M → $32.3M (+$18.8M)
113% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 8
13% more funds holding
Funds holding: 40 → 45 (+5)
0.13% more ownership
Funds ownership: 0.85% → 0.98% (+0.13%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$1.3M |
| 2 |
Renaissance Technologies
New York
|
+$739K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$699K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$548K |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
+$408K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EP
Eversept Partners
New York
|
-$440K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$93.9K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$85K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$66.4K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$30.4K |
CARM Hedge Fund Activity: Q3 2020 in Review
45 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q3 2020, worth a combined $32.3M — up 139% from $13.5M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new CARM positions and 3 closed out — a net gain of 5 holders — while 17 added to existing stakes and 8 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $1.3M. The largest seller was Eversept Partners, cutting an estimated $440K.
- 45 institutional investors held Carisma Therapeutics (CARM) as of Q3 2020, up from 40 in Q2 2020.
- Funds reported $32.3M of Carisma Therapeutics stock for Q3 2020, up 139% quarter-over-quarter.
- 8 funds opened new Carisma Therapeutics positions in Q3 2020 and 3 closed out, a net change of +5 holders.
- The largest Carisma Therapeutics buyer in Q3 2020 was Morgan Stanley, an estimated $1.3M added.
- The largest Carisma Therapeutics seller in Q3 2020 was Eversept Partners, an estimated $440K sold.
Based on aggregated 13F filings for Q3 2020.